| Tbio | Tumor necrosis factor receptor superfamily member 13C |
B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.
B cell-activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of Baff in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival. [provided by RefSeq, Jul 2008]
B cell-activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of Baff in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Common variable immunodeficiency | 101 | 5.224 | 2.6 |
| Brain Injuries | 65 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| osteosarcoma | 7950 | 3.0e-09 |
| primary Sjogren syndrome | 735 | 3.1e-05 |
| tuberculosis | 2010 | 4.6e-04 |
| nasopharyngeal carcinoma | 1058 | 5.0e-04 |
| interstitial cystitis | 2312 | 1.1e-03 |
| ulcerative colitis | 1819 | 1.2e-02 |
| sonic hedgehog group medulloblastoma | 467 | 1.6e-02 |
| ductal carcinoma in situ | 1745 | 2.3e-02 |
| primitive neuroectodermal tumor | 3035 | 2.6e-02 |
| Disease | log2 FC | p |
|---|---|---|
| ductal carcinoma in situ | 2.000 | 2.3e-02 |
| interstitial cystitis | 3.800 | 1.1e-03 |
| nasopharyngeal carcinoma | -2.200 | 5.0e-04 |
| osteosarcoma | -3.329 | 3.0e-09 |
| primary Sjogren syndrome | 3.000 | 3.1e-05 |
| primitive neuroectodermal tumor | 1.400 | 2.6e-02 |
| sonic hedgehog group medulloblastoma | 1.100 | 1.6e-02 |
| tuberculosis | -1.500 | 4.6e-04 |
| ulcerative colitis | 2.200 | 1.2e-02 |
| Accession | Q96RJ3 |
| Symbols |
BAFFR CD268 CVID4 BAFF-R BROMIX prolixin |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA | ||
| OMA EggNOG | ||
| Inparanoid OMA | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG |
